Last updated: February 14, 2026
What is NDC 82009-0124?
NDC 82009-0124 refers to a specific drug identified by the National Drug Code. Based on public databases, this NDC corresponds to Lumateperone (brand name: Caplyta), approved by the FDA in December 2019 for the treatment of schizophrenia in adults. Lumateperone is a second-generation antipsychotic with a novel mechanism of action targeting serotonin and dopamine receptors.
Market Landscape for Lumateperone (Caplyta)
Market size and demand drivers
- Prevalence of schizophrenia: Affects roughly 20 million globally. U.S.-specific estimates cite around 2.5 million diagnosed cases.
- Market penetration: As of 2023, Lumateperone accounts for an estimated 2%–5% of the antipsychotic market in the U.S., reflecting its relatively recent approval and positioning as a treatment with a favorable side effect profile.
- Key competitors: Risperidone, olanzapine, quetiapine, aripiprazole, brexpiprazole, and cariprazine.
Regulatory and reimbursement landscape
- FDA approval (Dec 2019): Granted for schizophrenia based on phase 3 clinical trial data showing efficacy and tolerability.
- Insurance coverage: Generally favorable, with reimbursements aligned with other second-generation antipsychotics, although formulary positioning is competitive.
Pipeline and future prospects
- Additional indications: Currently under investigation for bipolar disorder, depression, and other neuropsychiatric conditions.
- Lifecycle status: Market penetration remains modest; incremental growth expected as clinical awareness and coverage expand.
Price Projections and Revenue Forecasts
Current pricing and reimbursement environment
- Wholesale Acquisition Cost (WAC): Listed at approximately $750–$900 per month per patient in the U.S.
- Average net price: After discounts and rebates, estimated at $300–$600 per month.
- Pricing competitiveness: Slightly higher than older generics but lower than some specialty meds like brexpiprazole or cariprazine.
Projected revenue Estimates:
| Year |
Estimated Market Share |
Estimated Patients (U.S.) |
Revenue (USD millions) |
| 2023 |
3% |
75,000 |
$270 |
| 2024 |
4% |
100,000 |
$480 |
| 2025 |
5% |
125,000 |
$675 |
Assumptions: Steady tumor growth in schizophrenia populations, increasing prescriber familiarity, and expanding formulary inclusion.
Price trajectory assumptions
- Stable pricing with minor reductions: As competition intensifies, especially from generic formulations and biosimilars, prices could decline approximately 10%–15% from current levels over 2–3 years.
- Potential for premium pricing: If newer indications (bipolar, depression) gain approval, pricing might elevate, especially in niche markets.
Competitive Factors and Market Risks
- Label expansion: Approval for additional indications could boost sales.
- Generic entry: Patent expiry or biosimilar developments could compress prices significantly within 3–5 years.
- Market share losses: Older antipsychotics with established generics and branded drugs with broader indications could limit Lumateperone’s growth.
Key Takeaways
- Lumateperone (NDC 82009-0124) is an emerging competitor in the second-generation antipsychotic market.
- U.S. market penetration remains modest but is projected to grow at approximately 1–2 percentage points annually over the next three years.
- Pricing is currently stable but faces downward pressure from generics and biosimilars.
- Revenue projections estimate a range of $270 million to $675 million by 2025, assuming continued clinical adoption and formulary inclusion.
- Future expansion into bipolar disorder and other indications could significantly influence revenue streams.
FAQs
1. What factors influence the price of Lumateperone?
Pricing is affected by manufacturing costs, competitive market dynamics, payer negotiations, formulary placements, and the extent of clinical adoption.
2. How does Lumateperone compare to other antipsychotics in terms of pricing?
Its current cost per patient is comparable to branded second-generation antipsychotics, generally ranging from $600–$900 per month. Older generics can cost under $100 monthly.
3. What is the likelihood of biosimilar or generic entry?
Given its patent status, reduced protection might occur within 3–5 years, introducing generics that could lower prices and market share.
4. How might additional indications impact revenue?
Approval for bipolar disorder or depression could increase patient population and sales volume, creating premium pricing opportunities.
5. Are there geographic differences in the market?
Data primarily relate to the U.S.; international markets often have different pricing, approval statuses, and competitor landscapes, affecting global revenue estimations.
References
- FDA. Lumateperone approval letter. 2019.
- IQVIA. National Prescription Audit. 2022.
- EvaluatePharma. World Pharmaceutical Market Outlook. 2023.
- Prescriber and formulary data from U.S. commercial databases. 2023.
- Manufacturer’s pricing disclosures and market reports. 2023.
